Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM12GN7)

• Drug Name: CB-5083 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 73051434
  CAS Number: CAS 1542705-92-9
  TTD Drug ID: DM12GN7

Molecule-Related Drug Atlas

Drug(s) Targeting Valosin-containing protein p97 (VCP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CB-5339	DMOXDIY	Acute myeloid leukaemia	2A60	Phase 1	[5]

Drug(s) Affected By E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[6]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[7]
Betaine	DMGRZW2	Cystitis	GC00	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[8]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[9]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[10]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[11]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[6]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Valosin-containing protein p97 (VCP)	TTHNLSB	TERA_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)	OTBTA03N	MARH6_HUMAN	Protein Interaction/Cellular Processes	[4]
Transitional endoplasmic reticulum ATPase	OTWIX1JU	TERA_HUMAN	Gene/Protein Processing	[4]

References

• [1] ClinicalTrials.gov (NCT02243917) A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479.
• [4] Cholesterol increases protein levels of the E3 ligase MARCH6 and thereby stimulates protein degradation. J Biol Chem. 2019 Feb 15;294(7):2436-2448. doi: 10.1074/jbc.RA118.005069. Epub 2018 Dec 13.
• [5] Clinical pipeline report, company report or official report of Cleave Therapeutics.
• [6] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [7] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [8] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [9] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [10] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [11] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.